Hugel
Financials
Valuation Metrics
Hugel's Market Cap is ₩2.7T. At end of 2025 it was ₩2.9T. Ranked #169 of 2,421 in KR market (top 7%), #28 of 1,640 on KOSDAQ (top 2%), #14 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 6%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 2.68T KRW | KR#169/2,421 Sec#14/231 |
| Revenue | 479.57B KRW | KR#634/2,421 Sec#33/231 |
| Net Income | 163.22B KRW | KR#175/2,421 Sec#10/231 |
| Total Assets | 1.19T KRW | KR#434/2,421 Sec#23/231 |
| Net Assets | 1.09T KRW | KR#278/2,421 Sec#15/231 |
| Employees | 609 | KR#412/2,421 Sec#35/231 |
| Value | ||
| P/E | 16.41x | KR#1,089/2,421 Sec#66/231 |
| P/B | 2.46x | KR#2,033/2,421 Sec#156/231 |
| PEG | 1.76x | KR#784/2,421 Sec#50/231 |
| P/S | 5.58x | KR#2,170/2,421 Sec#143/231 |
| EV/EBITDA | 11.71x | KR#700/2,421 Sec#37/231 |
| FCF Yield | 5.10% | KR#843/2,421 Sec#43/231 |
| Profitability | ||
| ROE | 15.00% | KR#324/2,421 Sec#21/231 |
| ROA | 13.69% | KR#141/2,421 Sec#11/231 |
| Op. Margin | 43.56% | KR#18/2,421 Sec#5/231 |
| Revenue Growth | 18.88% | KR#583/2,421 Sec#54/231 |
| Earnings Growth | 9.30% | KR#758/2,421 Sec#50/231 |
| Financial Health | ||
| Debt Ratio | 9.57% | KR#131/2,421 Sec#28/231 |
| Total Debt | 26.30B KRW | KR#1,287/2,421 Sec#100/231 |
| FCF | 136.66B KRW | KR#146/2,421 Sec#6/231 |
| Cash | 259.56B KRW | KR#222/2,421 Sec#7/231 |
| Current Ratio | 7.55x | KR#158/2,421 Sec#34/231 |
| Net Debt/EBITDA | -1.12x | KR#359/2,421 Sec#18/231 |
| Performance | ||
| 1Y Return | -31.63% | KR#1,608/2,421 Sec#128/231 |
| 1M Return | -13.36% | KR#2,203/2,421 Sec#186/231 |
| From 52W High | -35.93% | KR#743/2,421 Sec#50/231 |
| 1Y MDD | -34.76% | KR#397/2,421 Sec#29/231 |
| Trading | ||
| Volume | 148,840 shares | KR#598/2,421 Sec#48/231 |
| Trading Value | 32.43B KRW | KR#116/2,421 Sec#6/231 |
| Foreign Own. | 58.53% | KR#21/2,421 Sec#1/231 |
| Per Share | ||
| EPS | 13,042 KRW | KR#84/2,421 Sec#6/231 |
| BPS | 86,924 KRW | KR#160/2,421 Sec#8/231 |
Company Info
Established in 2001, this global medical aesthetics company listed on KOSDAQ in 2015 and absorbed Hugel Pharma in 2018. Its core business involves the research, development, manufacturing, and sales of Type A botulinum toxin and hyaluronic acid fillers, including products like BOTULAX, The Chaeum, and Wellage. The company drives innovation through technologies such as artificial intelligence and robotics, providing comprehensive solutions for diverse aesthetic needs to enhance corporate value. Hugel was established in 2001 and is headquartered in Chuncheon-si, Gangwon Special Self-Governing Province.